Ekso Revenue Falls 58 Percent in Q2

Ekso Bionics (NASDAQ:EKSO), a developer of wearable robotic exoskeletons primarily for medical rehabilitation and mobility assistance, reported second quarter 2025 earnings on July 28, 2025. The most important news in the release was revenue dropping to $2.1 million for Q2 2025, missing analyst expectations of $4.31 million for Q2 2025 by more than 50%. This underperformance was due to delays in Enterprise Health device sales. The company recorded a net loss of $(2.7) million for Q2 2025 and Gross margin declined from 53% in Q2 2024 to 40% in Q2 2025. While earnings per share were a narrower loss than expected at $(1.24) for Q2 2025, the results overall showed significant challenges for the quarter, with management attributing the revenue shortfall to postponed, rather than lost, enterprise deals. The period was marked by uncertainty about demand and financial flexibility despite some bright spots in the personal device segment. Source: Analyst estimates for the quarter provided by FactSet. Ekso Bionics specializes in designing and building robotic exoskeletons for people with mobility impairments. These wearable medical devices help individuals regain movement, especially after spinal cord injuries or neurological conditions. The company's solutions serve two main markets: Enterprise Health (such as rehabilitation centers and hospitals) and Personal Health (home-use devices for individuals).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool